Published in Oncolytic Virother on January 23, 2015
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol (2000) 2.63
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.45
Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 2.15
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther (2003) 2.05
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A (2013) 1.75
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther (2007) 1.63
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet (1993) 1.53
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol (2006) 1.42
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther (2004) 1.35
Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev (2010) 1.33
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther (2006) 1.32
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One (2008) 1.30
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther (2006) 1.29
Reovirus therapy of lymphoid malignancies. Blood (2002) 1.28
Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant (2014) 1.28
Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol (1985) 1.23
Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia (2009) 1.22
Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med (2011) 1.22
Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res (2010) 1.19
Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol (1992) 1.18
Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol (2004) 1.16
Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res (2013) 1.11
Measles virus receptors: SLAM and CD46. Rev Med Virol (2004) 1.09
Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. J Leukoc Biol (1992) 1.08
Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med (2001) 1.08
Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood (2003) 1.07
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant (2012) 1.06
Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol (2005) 1.05
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood (1995) 1.03
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol (2007) 1.00
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet (1996) 0.99
Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther (2010) 0.98
Oncolytic myxoma virus: the path to clinic. Vaccine (2013) 0.95
Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res (2012) 0.95
Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther (2009) 0.94
Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res (2012) 0.94
Parvovirus infection-induced cell death and cell cycle arrest. Future Virol (2010) 0.94
Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology (2010) 0.93
Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res (2009) 0.93
Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today (2005) 0.93
A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res (2001) 0.92
Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer (1997) 0.90
Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. PLoS One (2012) 0.89
Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med (1978) 0.87
HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther (2013) 0.86
Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res (2011) 0.86
Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia (2008) 0.86
Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood (1991) 0.86
Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma. Clin Cancer Res (2001) 0.86
Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One (2011) 0.86
Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther (2009) 0.85
Hematopoietic stem cell transplantation. Stem Cells Cloning (2010) 0.84
E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med (2009) 0.83
The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn J Exp Med (1987) 0.83
Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. Clin Cancer Res (2013) 0.82
A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow. Clin Cancer Res (2006) 0.82
Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Blood Cancer J (2013) 0.82
Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? Crit Rev Oncol Hematol (2002) 0.82
Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol (2002) 0.82
CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy. Gene Ther (2010) 0.81
Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant (2010) 0.81
Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med (1979) 0.81
Reovirus as a successful ex vivo purging modality for multiple myeloma. Bone Marrow Transplant (2013) 0.81
The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol (2001) 0.80
Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol (1996) 0.80
Selective elimination (purging) of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus. Cancer Gene Ther (1997) 0.79
Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. Br J Haematol (2002) 0.79
Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. Oncol Rep (2011) 0.79
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Clin Cancer Res (1999) 0.78
Adhesion molecules on CD34+ hematopoietic cells in normal human bone marrow and leukemia. Ann Hematol (1992) 0.76
Ex vivo expansion of mafosfamide-purged PBPC products. Cytotherapy (2006) 0.76
Purging of human breast cancer cells from stem cell products with an adenovirus containing p53. Cancer Gene Ther (2000) 0.76
Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant (2000) 0.76
Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. Cancer Gene Ther (2001) 0.76
The incidence of tumor cell contamination of peripheral blood stem cells: a meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematol (2013) 0.76